Sushmita Sen, Global Medical Scientific Alliances of Oncology and Hematology of Roche, shared a post on LinkedIn:
“Each year The Cancer Drug Development Forum (CDDF) brings us all together to get real about the topics each stakeholder discusses behind their own closed doors. This meeting creates a safe place for us to bring topics that we all care about and yet don’t feel comfortable to discuss openly.
As I reflect on the discussions from the meeting earlier this week, I realized how far we have actually come on this platform.
Have we solved all the problems we face on Cancer Care? No, we did not. However, the fact that regulators, patients, payers, clinicians, academics and industry sit together for 3 days to understand each other’s perspectives is already a tremendous step towards the solution.
There is still a tug of war between the expectations of what science can deliver and what patients really need. The disconnect between personalized care options with the generalizability of evidence is getting bigger. And this tension led us to discuss importance of Patient Relevant Outcomes, Representative Data and how we evaluate their Value when it comes to making decisions on safety, efficacy and effectiveness of an innovation.
Ultimately, evidence generation must be meaningful, relevant while still answering the scientific question at hand. And we cannot do better if we don’t have the Dialogue and share our Perspectives to shape the future of care in oncology. And this is exactly what The Cancer Drug Development Forum (CDDF) is striving to achieve.
There were too many insights from the meeting, so I’m sharing a few below in images that stood out to me.
Ruth Plummer, Thierry Coppens, Jaap Verweij, Rosa Giuliani, Axel Glasmacher, Giorgia Campagnano, Shannon Adeux, Hyunmin Park, Mark Lawler, Fergus Sweeney – thanks for another fantastic meeting!”
Mark Lawler, Associate Director of Postgraduate Studies, Chair in Translational Cancer Genomics, and Professor of Digital Health at Queen’s University Belfast, shared a post by Sushmita Sen, adding:
“Great summary by Dr. Sushmita Sen of the The Cancer Drug Development Forum (CDDF) and what we are trying to achieve. I just started as the new Chair of CDDF towards the end of last year (taking over from my great colleague Ruth Plummer (a hard act to follow) – Ruth has stepped into the role of Managing Director).
We’ve just finished our annual Conference which took place this year in the lovely city of Ghent. Highlight for me has to be engaging in a fireside chat with Emer Cooke Executive Director European Medicines Agency – Emer gave us great insight on the EMA and its crucial role, reflecting on the last 5 years and the challenges and opportunities. A truly inspiring event – I’m still getting amazing feedback from attendees who were onsite and online.”
Other articles featuring Sushmita Sen and Mark Lawler on OncoDaily.
